Synapse

← Heart Drug

Papers in Heart Drug

Page 1 · newest first

  1. Inhibition of the Renin-Angiotensin System and Atrial Fibrillation in Heart FailureHeart Drug · 2005
  2. Thromboembolic Prophylaxis with Fondaparinux in Major Orthopaedic Surgery: Outcomes and CostsHeart Drug · 2005
  3. Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic SyndromeHeart Drug · 2005
  4. Nesiritide Usage in Decompensated Heart Failure: Cost Effectiveness and Clinical EffectivenessHeart Drug · 2005
  5. ACE Inhibitors for Older Patients with Heart Failure: A Review of Evidence, Practice Patterns and ChallengesHeart Drug · 2005
  6. Arrhythmogenic Right Ventricular Cardiomyopathy: A Presentation of Thirty Consecutive PatientsHeart Drug · 2005
  7. Rationale and Design of the OACIS-LIPID Study That Evaluates Early Use of Pravastatin in Acute Myocardial InfarctionHeart Drug · 2005
  8. Reduction of Soluble E-Selectin after Combined Treatment with Simvastatin and Vitamins C and EHeart Drug · 2005
  9. Pharmacological Basics of ƒ-Current InhibitionHeart Drug · 2005
  10. Additional Features of Beta-BlockersHeart Drug · 2005
  11. Nicorandil – Review of Pharmacological Properties and Clinical ApplicationsHeart Drug · 2005
  12. Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk PatientsHeart Drug · 2005
  13. Utility of Intravenous β-Blocker Administration in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous InterventionHeart Drug · 2005
  14. Hyperglycemia after Acute Ischemic Stroke: Prediction, Significance and Immediate Control with Insulin-Potassium-Saline-Magnesium InfusionsHeart Drug · 2005
  15. Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Days’ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) TrialHeart Drug · 2005
  16. Potassium Must Be Considered in Congenital Long QT SyndromeHeart Drug · 2005
  17. Association of Dyslipidemia and Concomitant Risk Factors with In-Hospital Mortality in Acute Coronary Syndrome in SwitzerlandHeart Drug · 2005
  18. Clinical Pharmacology of If Current InhibitionHeart Drug · 2005
  19. Clinical Efficacy of IvabradineHeart Drug · 2005
  20. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial HypertensionHeart Drug · 2004
  21. Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential ProblemsHeart Drug · 2004
  22. Prognostic Comparison of the Minute Ventilation/Carbon Dioxide Production Ratio and Slope in Patients with Heart FailureHeart Drug · 2004
  23. Changes in Peak Respiratory Flow and Quality of Life during Nebivolol TherapyHeart Drug · 2004
  24. The Efficacy of Colchicine in the Treatment of Recurrent Pericarditis Related to Postcardiac Injury (Postpericardiotomy and Postinfarcted) Syndrome: A Multicenter AnalysisHeart Drug · 2004
  25. Peripheral Chemoreceptor Contributions to Cardiovascular RegulationHeart Drug · 2004
  26. Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary SyndromesHeart Drug · 2004
  27. Low-Molecular-Weight Heparin in Acute Coronary SyndromesHeart Drug · 2004
  28. Methods for the Evaluation of Vascular ReconstructionHeart Drug · 2004
  29. Regulation of Hemostasis by the Sympathetic Nervous System: Any Contribution to Coronary Artery Disease?Heart Drug · 2004
  30. ACE Inhibitor, Angiotensin II Receptor Antagonist, Monotherapy or Combined Therapy?Heart Drug · 2004
  31. Integrilin Dose Optimization Using Cone Plate Analyzer – What Have We Learned Thus FarHeart Drug · 2004
  32. Age-Dependent Therapeutic Effects of Once-Daily Molsidomine Used as an Add-On Treatment in Patients with Stable Angina pectorisHeart Drug · 2004
  33. Prognostic Value of INR Fluctuations during Anticoagulant Therapy in Patients with Atrial Fibrillation and a High Thromboembolic RiskHeart Drug · 2004
  34. Effect of Pulmonary Vein Isolation on Quality of Life in Patients with Paroxysmal Atrial FibrillationHeart Drug · 2003
  35. Validation of a Multicenter Registry Database of Intra-Aortic Balloon Pumping in a Variety of Clinical SettingsHeart Drug · 2003
  36. Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular RiskHeart Drug · 2003
  37. Interim Analyses in Clinical TrialsHeart Drug · 2003
  38. Nuclear Cardiology Core Laboratory: State of the ArtHeart Drug · 2003
  39. Assessment of Quality of Life in Pharmacological Treatment of Atrial FibrillationHeart Drug · 2003
  40. Blinded End Point Adjudication in the ‘Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Coronary Angioplasty in Acute Myocardial Infarction’ (DANAMI-2 Trial)Heart Drug · 2003
  41. New Insights into Molecular Mechanisms of Atrial Fibrillation: Are We Approaching Possible Novel Pharmacological Principles for Treating This Disorder?Heart Drug · 2003
  42. Intraoperative Stress EchocardiographyHeart Drug · 2003
  43. Review of Cardiovascular Disease in Women: Awareness, Prevention, and Psychosocial CharacteristicsHeart Drug · 2003
  44. Right Heart Catheterization: Indications, Technique, Safety, Measurements, and AlternativesHeart Drug · 2003
  45. Add-On Benefit to Coronary Artery Bypass Grafting of Treatment with Ramipril for Major Cardiac Events and Left Ventricular Remodeling in Intermediate-Risk PatientsHeart Drug · 2003
  46. Early Drug Therapy and In-Hospital Mortality following Acute Myocardial InfarctionHeart Drug · 2003
  47. Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for EchocardiographyHeart Drug · 2003
  48. Atrial Fibrillation: Rhythm or Rate Control?Heart Drug · 2003
  49. Statistical Methods in Genomics ResearchHeart Drug · 2003
  50. Emerging Role of the Urotensin II System in Cardiovascular DiseaseHeart Drug · 2003